Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

Only registered users can translate articles

The link is saved to the clipboard

StatusRecruiting

Keywords

Abstract

Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of 2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of Buenos Aires.

Institutions. Hospitals San Juan de Dios, Simplemente Evita, Dr. Carlos Bocalandro, Evita Pueblo, Sanatorio Antartida, Hospital Central de San Isidro, Clinica Olivos in the state of Buenos Aires with 38 regional and town hospitals acting as referral centers, and Hospital Militar Central, Sanatorio de Los Arcos, Hospital Universitario CEMIC, Sanatorio Sagrado Corazon, Sanatorio Finochietto, Sanatorio Anchorena, Centro Gallego, and in the city of Buenos Aires in Argentina.

Study population. Subjects >= 75 years of age irrespective of presenting comorbidities or between 65-74 years of age with at least one comorbidity (hypertension, diabetes, obesity, chronic renal failure, and COPD) who experience the following signs and symptoms for less than 48 hours at the time of screening for SARS CoV2 by RT-PCR: (a) a temperature >=37.5°C and/or unexplained sweating and/or chills and (b) at least one of the following: dry cough, dyspnea, fatigue, myalgia, anorexia, sore throat, loss of taste and/or smell, rhinorrhea. Subjects consenting to screening will be tested by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV-2 in a nasopharyngeal and an oropharyngeal swab and invited to participate when RNA for the virus is detected.

Intervention. Eligible, consenting patients will be randomized using an electronic system to receive 250 ml of convalescent plasma with an IgG titer against SARS-CoV2 spike (S) protein >1:1,000 (COVIDAR IgG, Insituto Leloir, Argentina) or placebo (normal saline 0.9%) administered in a 1:1 ratio. Both treatment and placebo will be concealed using dark bags and tape to cover the infusion line. Treatment will be administered <72 hours from initiation of symptoms. Subjects will be monitored for 12 hours after treatment for adverse events.

Clinical and laboratory monitoring. All participating subjects will be admitted to the hospital upon enrollment. Twenty-four hours after completing the infusion, a sample of venous blood (5 ml) will be obtained from all participants to measure anti-S IgG SARS-CoV2 in serum (COVIDAR IgG, Leloir) and preserved at -20°C until completion of the study. Patient evolution will be assessed daily by study physicians during hospitalization until day 25 and/or at home until day 15, in the event of earlier discharge from the hospital. Study physicians will use predesigned questionnaires to collect clinical information. An Independent Data Safety Monitoring Board (DSMB) will supervise participating subjects during the study.

Endpoints. The primary endpoint of the trial is development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93% when breathing room air determined using a predefined protocol. Three other clinical endpoints include (a) life threatening respiratory disease, defined as need for 100% oxygen supplementation and/or non-invasive or invasive ventilation and/or admission to intensive care; (b) critical systemic illness, defined as respiratory failure (PaO2/FiO2 ≤ 200 mm Hg) and/or shock and/or multiorganic distress syndrome; and (c) death.

Statistical analysis. The study is designed to have one interim analysis when the outcome results for 50% of the subjects is obtained. The minimally clinically important difference was set at a 40% relative reduction for an expected outcome rate of 50% in the control group reduced to 30% in the intervention group. A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction.

Ethical considerations. The trial has been approved by the institutional review boards of participating institutions and the Central Ethics Committee of the state of Buenos Aires. The study will be conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization. Written informed consent will be obtained from all patients for screening and enrollment.

Dates

Last Verified:	06/30/2020
First Submitted:	06/28/2020
Estimated Enrollment Submitted:	07/18/2020
First Posted:	07/20/2020
Last Update Submitted:	07/18/2020
Last Update Posted:	07/20/2020
Actual Study Start Date:	06/03/2020
Estimated Primary Completion Date:	07/29/2020
Estimated Study Completion Date:	07/29/2020

Condition or disease

COVID

Intervention/treatment

Biological: Plasma

Other: Placebo

Phase

Arm Groups

Arm	Intervention/treatment
Experimental: Plasma Convalescent plasma with an IgG titer against SARS-CoV2	Biological: Plasma 250 ml Convalescent plasma with an IgG titer against SARS CoV2
Placebo Comparator: Placebo Normal Saline 0.9%	Other: Placebo Normal Saline 0.9%

Eligibility Criteria

Ages Eligible for Study	65 Years To 65 Years
Sexes Eligible for Study	All
Accepts Healthy Volunteers	Yes
Criteria	Inclusion Criteria: - Age ≥ 75 or age 65-74 with at least 1 of the following comorbidities: arterial hypertension, diabetes, obesity, chronic obstructive pulmonary disease, heart disease, chronic kidney disease - Last 48 hours: (A)Axillary temperature ≥ 37.5oC or febrile equivalent, combined with (a) dry cough and/or (b) breathing difficulty and/or (c) odinophagia and/or (d) anosmia/dysgeusia and/or (e) any of the following symptoms: fatigue, anorexia, myalgias or rhinorrhea. - Confirmed diagnosis SARS-Cov2 by RT-PCR - Give Informed consent Exclusion Criteria: - Severe respiratory disease - Cardiac insufficiency, - Chronic renal failure, - Primary hypogammaglobulinemias, - Myelodysplastic syndromes, - Chronic linfoproliferative syndromes, - Monoclonal gammapathies, - Known hypersensitibility, - Active cancer, - HIV, HBV or HCV infection, - Chronic administration of immunosuppressants, - Body transplant history, - Chronic liver disease, Chronic lung disease with oxygen requirement.

Outcome

Primary Outcome Measures

1. Development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93% [From 12 hours post infusion to day 15 post infusion]

Secondary Outcome Measures

1. Life threatening respiratory disease [From 12 hours post infusion to day 25 post infusion]

2. Critical systemic illness, defined as respiratory failure [From 12 hours post infusion to day 25 post infusion]

3. Death [From 12 hours post infusion to day 25 post infusion]

Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

Keywords

covid-19

anorexia

pharyngitis

coronavirus infections

fatigue

chills

cough

dyspnea

respiratory insufficiency

myalgia

obesity